Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.51 |
| ▸ | REN | P00797 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.39 |
| ▸ | HPGD | P15428 | 4/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6728676 | 0.82 | MAPT (0.52) | ATMNPC1RAB9ASMN1; SMN2IDO1 | |
| SCHEMBL5710347 | 0.81 | MAPT (0.51) | ATMRENIDO1MAPTL3MBTL1 | |
| SCHEMBL6719951 | 0.79 | L3MBTL1 (0.47) | RENNPC1RAB9ASMN1; SMN2IDO1 | |
| SCHEMBL6721503 | 0.75 | ALDH1A1 (0.51) | ATMSMN1; SMN2IDO1HTR1AADRA1D | |
| SCHEMBL6721507 | 0.74 | SMN1; SMN2 (0.43) | RENNPC1RAB9ASMN1; SMN2IDO1 | |
| SCHEMBL1941923 | 0.74 | IDO1 (0.53) | RENSMN1; SMN2IDO1HTR1AADRA1D | |
| Hydrochloric Acid SCHEMBL2473227 | 0.73 | IDO1 (0.54) | RENSMN1; SMN2GAAIDO1HTR1A | |
| SCHEMBL20233717 | 0.73 | TDP1 (0.43) | RENL3MBTL1TDP1GABRA5 | |
| SCHEMBL6720057 | 0.72 | L3MBTL1 (0.51) | ATMNPC1RAB9ASMN1; SMN2HTR1A | |
| SCHEMBL5798261 | 0.71 | IDO1 (0.53) | IDO1HTR1AADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501830-B1 | 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2011-10-05 | — | — | EP | disclosed |
| US-20080312242-A1 | 7-ARYL-3, 9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS, LTD. (CH) | 2008-12-18 | — | — | US | disclosed |
| US-20080312242-A1 | 7-ARYL-3, 9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS, LTD. (CH) | 2008-12-18 | — | — | US | disclosed |
| US-20080312242-A1 | 7-ARYL-3, 9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS, LTD. (CH) | 2008-12-18 | — | — | US | disclosed |
| US-7427613-B2 | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-09-23 | — | — | US | disclosed |
| US-7427613-B2 | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-09-23 | — | — | US | disclosed |
| US-7427613-B2 | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-09-23 | — | — | US | disclosed |
| US-20070142363-A1 | Novel diazabicyclonene derivatives and use thereof | ACTELION PHARMACEUTICALS LTD (CH) | 2007-06-21 | — | — | US | disclosed |
| US-20070142363-A1 | Novel diazabicyclonene derivatives and use thereof | ACTELION PHARMACEUTICALS LTD (CH) | 2007-06-21 | — | — | US | disclosed |
| US-20070135405-A1 | Novel diazabicyclononene and tetrahydropyridine derivatives with a new polar side-chain | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-06-14 | — | — | US | disclosed |
| US-20070135405-A1 | Novel diazabicyclononene and tetrahydropyridine derivatives with a new polar side-chain | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-06-14 | — | — | US | disclosed |
| US-20070135406-A1 | Diazabicyclononene and tetrahydropyridine derivatives with a new side-chain | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-06-14 | — | — | US | disclosed |
| US-20070135406-A1 | Diazabicyclononene and tetrahydropyridine derivatives with a new side-chain | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-06-14 | — | — | US | disclosed |
| US-20070111989-A1 | Novel diazabicyclononene derivatives and use | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-05-17 | — | — | US | disclosed |
| US-20070111989-A1 | Novel diazabicyclononene derivatives and use | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-05-17 | — | — | US | disclosed |
| US-20050176700-A1 | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension,cardiovascular or renal diseases | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-08-11 | — | — | US | disclosed |
| WO-2005054244-A2 | AZABICYCLOOCTENE AND OTHER TETRAHYDROPYRIDINE DERIVATIVES WITH A NEW SIDE-CHAIN | ACTELION PHARMACEUTICALS LTD (CH) | 2005-06-16 | — | — | WO | disclosed |
| EP-1501830-A1 | 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | Actelion Pharmaceuticals Ltd. (CH) | 2005-02-02 | — | — | EP | disclosed |
| WO-2004105762-A1 | MEDICAL USE OF DIAZABICYCLONONENE DERIVATIVES AS INHIBITORS OF PARASITE ASPARTIC PROTEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2004-12-09 | — | — | WO | disclosed |
| WO-2003093267-A1 | 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111989-A1 | Novel diazabicyclononene derivatives and use | REN, ACE, AGTR1 | ATM 4773/4885REN 1/4885NPC1 1922/4885 |
| US-20070135406-A1 | Diazabicyclononene and tetrahydropyridine derivatives with a new side-chain | REN, ACE, ACE2 | ATM 4544/4885REN 1/4885NPC1 3500/4885 |
| US-20050176700-A1 | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension,cardiovascular or renal diseases | REN, AGTR1, ACE | ATM 4622/4885REN 1/4885NPC1 1326/4885 |
| US-20080312242-A1 | 7-ARYL-3, 9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | REN, AGTR1, ACE | ATM 4622/4885REN 1/4885NPC1 1326/4885 |
| US-20070135405-A1 | Novel diazabicyclononene and tetrahydropyridine derivatives with a new polar side-chain | REN, ACE, ACE2 | ATM 4700/4885REN 1/4885NPC1 3054/4885 |
| US-20070142363-A1 | Novel diazabicyclonene derivatives and use thereof | REN, ACE, PEPD | ATM 4484/4885REN 1/4885NPC1 1713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.